SINGAPORE, July 17 — Researchers have discovered four specific parts of Sars-CoV-2 — the virus that causes Covid-19 — that antibodies found in recovered Covid-19 patients were able to neutralise, thus limiting its spread.

This discovery will boost efforts to find a treatment for Covid-19 and factor significantly in the development of a vaccine.

The breakthrough, a key milestone in the global battle against the Covid-19 pandemic, was jointly announced today by the National Centre for Infectious Diseases (NCID) and the Singapore Immunology Network (SIgN), a research institute established by the Agency for Science, Technology and Research.

When a person suffers from a viral infection, his body produces antibodies which try to attach themselves to parts of the virus, also known as epitopes, to try to neutralise and eliminate them.

But only some antibodies can eliminate the virus or offer protection against infection, NCID and SIgN said in a joint statement. This depends on the epitopes the antibodies are targeting.

The two organisations conducted studies which identified four epitopes that antibodies found in Covid-19 patients could attach themselves to.

The four epitopes are called S14P5, S21P2, S20P2 and N4P5.

Tests conducted on more than 100 recovering Covid-19 patients found these epitopes in those who were infected, making them good "detection markers” to identify patients who have been exposed to Sars-CoV-2.

SIgN will be using these epitopes in a multi-centre collaborative study for the development of the World Health Organisation’s International Standard for Covid-19 antibody and Reference Panel.

The findings will enable the health authorities to:

●   Detect the presence of Sars-CoV-2 in individuals who might have had negative results with the polymerase chain reaction test

●   Estimate the community’s immunity to Covid-19 infection by surveying the degree to which the population carries antibodies that can neutralise these epitopes

●   Support the development of treatments and vaccines

Professor Leo Yee Sin, the executive director of NCID, said the coronavirus has challenged the entire scientific world with numerous unresolved questions awaiting scientists to unravel.

"Antibodies are key to our bodies’ defence mechanisms against viruses,” he said. "We are pleased to share this internationally leading work by the local research team which focuses on a powerful aspect of finding out how humans can generate specific antibodies targeted against Sars-CoV-2.”

Professor Lisa Ng, senior principal investigator with SIgN, added that the identification of the epitopes of the virus is a "crucial” advancement in the development of treating Covid-19.

"There is also potential to use these targets against similar coronaviruses to address other viral outbreaks,” she said. — TODAY